CD147 overexpression may serve as a promising diagnostic and prognostic marker for gastric cancer: evidence from original research and literature
Metrics: PDF 805 views | HTML 1915 views | ?
Chenghao Hu1,*, Xiaoxia Dong2,*, Junbo Wu 3,*, Feifan Xiao4,*, Jun Shang5, Liang Liu6, Yuan Yang7, Dongmei Luo8, Qiuting Li9, Qian Song4, Jingcheng Yang7, Chengdong Zhang7, Li Shen1 and Zhiguo Luo1
1 Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, PR China
2 Department of Pharmacology, School of Basic Medicine, Hubei University of Medicine, Shiyan, Hubei, PR China
3 Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, PR China
4 First Clinical Academy, Guangxi Medical University, Nanning, Guangxi, PR China
5 Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, PR China
6 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, PR China
7 School of Life Sciences, Fudan University, Shanghai, PR China
8 School of Mathematics and Physics, Anhui University of Technology, Maanshan, Anhui, PR China
9 Department of Clinical Oncology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China
* These authors have contributed equally to this work
Li Shen, email:
Zhiguo Luo, email:
Keywords: gastric cancer, CD147, original research, meta-analysis
Received: October 07, 2016 Accepted: February 06, 2017 Published: February 25, 2017
Gastric cancer (GC) is one of the most common malignancies worldwide. The expression of CD147 protein is associated with GC. However, the clinical role of CD147 in GC has not been investigated extensively. Hence, we focused on studying the association between the expression of CD147 and clinicopathological features of GC patients in this study. Firstly, sixteen publications (1752 cases and 391 controls) and one from our own original research (143 cases) were included in the meta-analysis to obtain a more precise estimation of the diagnostic value of CD147. The results showed that expression rate of CD147 in the GC group is higher than that in control group. Moreover, gender, TNM stage, lymph node metastasis, and depth of invasion are all associated with CD147. Further, sections of gastric tissue from 143 cases underwent immunohistochemical staining for evaluation of CD147 protein expression. Our retrospective analysis demonstrated CD147 protein expression was significantly associated with clinical N stage, and tumor stage. Meanwhile, it can also serve as an independent prognosis biomarker. In conclusion, our results support the role of CD147 as a good indicator of diagnosis and prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.